GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Tax Expense

Diamyd Medical AB (OSTO:DMYD B) Tax Expense : kr0.00 Mil (TTM As of Aug. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Tax Expense?

Diamyd Medical AB's tax expense for the months ended in Aug. 2024 was kr0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Aug. 2024 was kr0.00 Mil.


Diamyd Medical AB Tax Expense Historical Data

The historical data trend for Diamyd Medical AB's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Tax Expense Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Diamyd Medical AB Tax Expense Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines